Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Sells $82,636.42 in Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Dirk Kersten sold 2,357 shares of the business’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $35.06, for a total value of $82,636.42. Following the completion of the transaction, the director now owns 190,939 shares in the company, valued at approximately $6,694,321.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Dirk Kersten also recently made the following trade(s):

• On Monday, September 23rd, Dirk Kersten sold 40,831 shares of Dyne Therapeutics stock. The shares were sold at an average price of $35.32, for a total value of $1,442,150.92.
• On Friday, September 20th, Dirk Kersten sold 79,411 shares of Dyne Therapeutics stock. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95.

Dyne Therapeutics Price Performance

NASDAQ:DYN traded down $0.79 during midday trading on Friday, reaching $33.83. 517,754 shares of the company traded hands, compared to its average volume of 1,594,537. The firm has a market capitalization of $2.96 billion, a price-to-earnings ratio of -8.72 and a beta of 1.07. The company has a fifty day moving average price of $40.41 and a 200 day moving average price of $33.78. Dyne Therapeutics, Inc. has a twelve month low of $6.40 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.02. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -2.96 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently issued reports on DYN shares. Morgan Stanley upped their price target on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. StockNews.com cut shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 16th. Oppenheimer reissued an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright reaffirmed a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Finally, JPMorgan Chase & Co. boosted their price target on Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $51.40.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of DYN. Trexquant Investment LP bought a new position in Dyne Therapeutics in the 4th quarter worth approximately $304,000. Rafferty Asset Management LLC boosted its position in Dyne Therapeutics by 17.7% during the 4th quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after acquiring an additional 24,632 shares during the period. Commodore Capital LP acquired a new position in shares of Dyne Therapeutics during the fourth quarter valued at $11,970,000. Frazier Life Sciences Management L.P. bought a new stake in shares of Dyne Therapeutics during the fourth quarter valued at about $15,758,000. Finally, Octagon Capital Advisors LP raised its stake in shares of Dyne Therapeutics by 14.4% during the fourth quarter. Octagon Capital Advisors LP now owns 792,945 shares of the company’s stock valued at $10,546,000 after purchasing an additional 100,000 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.